Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact
100th anniversary
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews ...
Review Series
Vascular Malformations (Apr 2024)
Lung inflammatory injury and tissue repair (Jul 2023)
Immune Environment in Glioblastoma (Feb 2023)
Korsmeyer Award 25th Anniversary Collection (Jan 2023)
Aging (Jul 2022)
Next-Generation Sequencing in Medicine (Jun 2022)
New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
View all review series ...
Viewpoint
Collections
In-Press Preview
Commentaries
Research Letters
Letters to the Editor
Editorials
Viewpoint
JCI This Month
Top read articles
Clinical Medicine
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
D C Montefiori, … , L A Cavacini, M R Posner
D C Montefiori, … , L A Cavacini, M R Posner
Published August 1, 1993
Citation Information:
J Clin Invest.
1993;
92(2)
:840-847.
https://doi.org/10.1172/JCI116658
.
View:
Text
|
PDF
Research Article
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Text
PDF
Abstract
Authors
D C Montefiori, B S Graham, J Zhou, J Zhou, R A Bucco, D H Schwartz, L A Cavacini, M R Posner
×
Other pages:
840
841
842
843
844
845
846
847
Other pages:
840
841
842
843
844
845
846
847